摘要
目的:评价萘替芬酮康唑乳膏治疗足癣患者的成本与效果。方法:使用决策树模型评价萘替芬酮康唑乳膏与硝酸咪康唑乳膏、联苯苄唑乳膏以及酮康唑乳膏的成本与效果,得到患者1年的治疗费用和无治疗时间。临床参数来自萘替芬酮康唑乳膏的Meta分析研究。与治疗相关的成本和效果数据来自中国招标采购数据和上海当地医院。对分析结果进行单因素敏感性分析。结果:与其他3种外用抗真菌药物相比,萘替芬酮康唑乳膏最多可以增加0.1个无治疗月,同时卫生成本减少144.11元,萘替芬酮康唑乳膏为绝对优势方案。萘替芬酮康唑乳膏治疗有效率和足癣复发率是对分析结果影响较大的参数。结论:从中国卫生体系角度出发,足癣患者使用萘替芬酮康唑乳膏治疗更具有成本-效果。
Objective:To evaluate the cost-effectiveness of naftifine hydrochloride and ketoconazole cream in the treatment of tinea pedis.Methods:Decision tree model was used to evaluate the cost and effect of naftifine hydrochloride and ketoconazole cream,miconazole nitrate cream,bifonazole cream,and ketoconazole cream,and the treatment cost and treatment-free-months were obtained.Clinical parameters were derived from a Meta-analysis of naftifine hydrochloride and ketoconazole cream.The cost and effect data came from China’s bidding procurement data and local hospitals in Shanghai.An one-way sensitivity analysis was carried out to determine the robustness of this baseline result.Results:Compared with the other three topical antifungal drugs,naftifine hydrochloride and ketoconazole cream could increase the maximum of 0.1 treatment-free-months,while the cost was reduced by$144.11.Naftifine hydrochloride and ketoconazole cream was the absolute dominance plan.The effective rate of naftifine hydrochloride and ketoconazole cream and the probability of recurrence for tinea pedis was the most sensitive parameter.Conclusion:Naftifine hydrochloride and ketoconazole cream can be viewed as cost-effective for tinea pedis patients from a Chinese health system perspective.
作者
付洁
吴斌
万旭
范蓓蓓
Fu Jie;Wu Bin;Wan Xu;Fan Beibei(Department of Pharmacy,South Campus,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 201112,China;Department of Pharmacy,Shanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine)
出处
《药物流行病学杂志》
CAS
2020年第9期619-622,共4页
Chinese Journal of Pharmacoepidemiology
基金
上海市卫生计生系统重要薄弱学科建设项目(编号:2016ZB0304)。
关键词
萘替芬酮康唑
足癣
成本-效果分析
Naftifine hydrochloride and ketoconazole
Tinea pedis
athlete’s foot
Cost-effectiveness analysis
